Trial Profile
A phase II Study of Bevacizumab plus oral S1 previously treated non-small cell lung Cancer (OSAKA-LCSG1202)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Dec 2018
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Gimeracil/oteracil/tegafur (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 07 Jul 2017 Status changed from recruiting to completed.
- 01 Jun 2017 Primary endpoint (Objective clinical response rate) has not been met as per the results published in the Cancer Chemotherapy and Pharmacology
- 01 Jun 2017 Results published in the Cancer Chemotherapy and Pharmacology